Innovent Reports PCSK-9 mAb Meets Endpoint in Hypercholesterolemia Trials
publication date: Feb 17, 2022
Suzhou Innovent reported that IBI306, the company's recombinant fully-human anti-PCSK-9 mAb, met the primary endpoint of lowering low-density lipoprotein cholesterol in two China registrational trials. One of the trials enrolled patients with non-familiar hypercholesterolemia (non-FH) patients at high/very high cardiovascular risk and the second trial enrolled patients with both non-FH and heterozygous familial hypercholesterolemia. Innovent, which has now completed three registrational trials of the candidate, will release data from the trials at an upcoming academic conference. More details....
Stock Symbol: (HK: 01801)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.